Lenalidomide (CC-5013): Advancing Cancer Immunotherapy vi...
2026-01-20
Discover how Lenalidomide (CC-5013), an oral thalidomide derivative, is transforming cancer immunotherapy research through multifaceted immune and angiogenesis modulation. This article uniquely explores the integration of epigenetic control, innate immunity, and translational applications, offering advanced insights for hematologic malignancy models.